The company diverges from Summit and Bristol/BioNTech with a pivotal endometrial trial.
ApexOnco Front Page
Recent articles
Parabilis’s zolucatetide bids to be third to a rather small market.
Two new pivotal Chinese first-line trials have started in lung cancer.
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
The company will start a phase 2/3 trial of PF-08634404 in March.
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
